Balyasny Asset Management
VC Fund
Chicago, United States
Balyasny Asset Management is a VC fund in Chicago focused on Biotechnology and FinTech. Founded in 2001, Balyasny Asset Management (BAM) is a global asset management firm dedicated to delivering consistent, uncorrelated absolute returns in all market environments. BAM's disciplined investment approach focuses on true alpha generation by combining a deep fundamental research team with an active risk management culture. The firmhas offices in the United States, London & Hong Kong with more than 500 employees representing greater than 45 countries.
- Total investments:
- 52
- Last investment:
- Lead investor:
- 10%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Balyasny Asset Management invests in
Stages Balyasny Asset Management invests in
Countries Balyasny Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6.1M–$179M
- Series C
- $50M–$350M
- Series D
- $35M–$225M
Investment Focus
Industry
- Biotechnology 5 (10%)
- FinTech 4 (8%)
- Analytics 4 (8%)
- Health Care 4 (8%)
- Machine Learning 4 (8%)
Stage
- Series D 6 (12%)
- Series A 5 (10%)
- Series C 3 (6%)
- Series F 3 (6%)
- Series B 2 (4%)
Country
- United States 20 (38%)
- China 1 (2%)
- Sweden 1 (2%)
- Belgium 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Magnell
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
Brad Downes
Associate Director - Strategic Finance
|
Associate Director - Strategic Finance | Total investments: 0 | Find email | |
David Black
Managing Director Business Development
|
Managing Director Business Development | Total investments: 0 | Find email | |
David Shaw
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
Douglas Cilento
Head of Macro Trading
|
Head of Macro Trading | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jasper Therapeutics
|
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $132M / Post-IPO Equity / Jul 16, 2026 | |
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | |
Oak hill bio
|
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M / Series A / Jun 01, 2026 | |
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | |
Cellectar Biosciences
|
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M / Post-IPO Equity / May 05, 2026 | |
Coultreon Biopharma
|
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | |
Sagimet Biosciences
|
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M / Post-IPO Equity / Apr 27, 2026 | |
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M / Post-IPO Equity / Apr 16, 2026 | |
Ovid Therapeutics
|
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M / Post-IPO Equity / Mar 17, 2026 | |
Relmada Therapeutics
|
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M / Post-IPO Equity / Mar 09, 2026 | |
| See all 52 investments → | |||
Co-Investors
Janus Henderson Investors
11 deals together
IVP
7 deals together
Adage Capital Management
6 deals together
Coastlands Capital
6 deals together
Columbia Threadneedle Investments
6 deals together
Nantahala Capital Management
6 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Balyasny Asset Management invest in?
Balyasny Asset Management invests primarily in Biotechnology, FinTech and Analytics startups, most often at Series D and Series A stage. Most of the 52 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Balyasny Asset Management's check size?
Balyasny Asset Management typically joins rounds of $6.1M–$179M at Series A, $50M–$350M at Series C and $35M–$225M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Balyasny Asset Management participates in.
How do I contact Balyasny Asset Management?
Public channels for Balyasny Asset Management include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Balyasny Asset Management?
The team at Balyasny Asset Management includes Michael Magnell (Senior Analyst), Brad Downes (Associate Director - Strategic Finance) and David Black (Managing Director Business Development), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
